| Assessment Status | Rapid Review Complete |
| HTA ID | - |
| Drug | Fluticasone furoate/vilanterol |
| Brand | Relvar™ Ellipta™ |
| Indication | For both (i) the regular treatment of asthma in adults and adolescents aged 12 years and older where use of a combination product (long-acting beta-2-agonist and inhaled corticosteroid) is appropriate: patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short acting beta-2-agonist. and (ii) for symptomatic treatment of patients with COPD with a FEV1<70% of predicted normal (post-bronchodilator) in patients with an exacerbation history despite regular bronchodilator therapy. |
| Assessment Process | |
| Rapid review commissioned | 10/12/2013 |
| Rapid review completed | 23/12/2013 |
| Rapid review outcome | Full Pharmacoeconomic Evaluation not Recommended. |
